MSK
Search
- Page Path
- HOME > Search
Journal Article
- Comprehensive Analysis of Gut Microbiota Alteration in the Patients and Animal Models with Polycystic Ovary Syndrome
- Jing Zhou , Xuemei Qiu , Xuejing Chen , Sihan Ma , Zhaoyang Chen , Ruzhe Wang , Ying Tian , Yufan Jiang , Li Fan , Jingjie Wang
- J. Microbiol. 2023;61(9):821-836. Published online October 12, 2023
- DOI: https://doi.org/10.1007/s12275-023-00079-9
- 53 View
- 0 Download
- 3 Web of Science
- 3 Crossref
-
Abstract
- Polycystic ovary syndrome (PCOS) is a common disease of endocrine–metabolic disorder, and its etiology remains largely unknown. The gut microbiota is possibly involved in PCOS, while the association remains unclear. The comprehensive analysis combining gut microbiota with PCOS typical symptoms was performed to analyze the role of gut microbiota in PCOS in this study. The clinical patients and letrozole-induced animal models were determined on PCOS indexes and gut microbiota, and fecal microbiota transplantation (FMT) was conducted. Results indicated that the animal models displayed typical PCOS symptoms, including disordered estrous cycles, elevated testosterone levels, and ovarian morphological change; meanwhile, the symptoms were improved after FMT. Furthermore, the microbial diversity exhibited disordered, and the abundance of the genus Ruminococcus and Lactobacillus showed a consistent trend in PCOS rats and patients. The microbiota diversity and several key genera were restored subjected to FMT, and correlation analysis also supported relevant conclusions. Moreover, LEfSe analysis showed that Gemmiger, Flexispira, and Eubacterium were overrepresented in PCOS groups. Overall, the results indicate the involvement of gut microbiota in PCOS and its possible alleviation of endocrinal and reproductive dysfunctions through several special bacteria taxa, which can function as the biomarker or potential target for diagnosis and treatment. These results can provide the new insights for treatment and prevention strategies of PCOS.
-
Citations
Citations to this article as recorded by
- Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics
Vineet Singh, Kanika Mahra, DaRyung Jung, Jae-Ho Shin
Probiotics and Antimicrobial Proteins.2024; 16(5): 1744. CrossRef - Potential therapeutic application and mechanism of gut microbiota-derived extracellular vesicles in polycystic ovary syndrome
Liangliang Yang, Tingxiu Liu, Yan Liao, Yuehan Ren, Zheng Zheng, Mingyue Zhang, Yue Yu, Chang Liu, Chaoying Wang, Tong Chen, Lili Zhang, Dongxue Zheng, Haidan Zhao, Zhexin Ni, Xinmin Liu
Biomedicine & Pharmacotherapy.2024; 180: 117504. CrossRef - Research Advance on the Prevention and Treatment of Polycystic Ovary Syndrome Based on Dysbiosis of Gut Microbiota
钰炜 王
Advances in Clinical Medicine.2024; 14(08): 895. CrossRef
- Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics
First
Prev
TOP
